After-Hours Earnings Report for November 3, 2025 : PLTR, VRTX, WMB, SPG, O, FANG, FNV, SBAC, BWXT, CTRA, CRBG, HOLX

A diverse group of companies, including Palantir Technologies (PLTR), Vertex Pharmaceuticals (VRTX), and Williams Companies (WMB), are scheduled to report Q3 2025 earnings after hours on November 3, 2025. Analyst consensus forecasts indicate significant year-over-year EPS growth for firms like Palantir (+100%) and Franco-Nevada (+71.25%), while Diamondback Energy (FANG) and Corebridge Financial (CRBG) anticipate declines. The reports also detail 2025 Price-to-Earnings ratios, frequently implying higher growth expectations compared to industry averages for many of these firms, providing key insights into their valuations and future prospects.

Analysis

A diverse group of companies is set to report Q3 2025 earnings on November 3, 2025, with analyst consensus forecasts indicating varied performance across sectors. Palantir Technologies (PLTR) projects a robust 100.00% year-over-year EPS increase to $0.12, while Franco-Nevada (FNV) anticipates a 71.25% rise. Conversely, Diamondback Energy (FANG) and Corebridge Financial (CRBG) face expected EPS declines of 15.68% and 21.74%, respectively.

Many reporting firms exhibit significantly higher 2025 Price-to-Earnings (P/E) ratios compared to their industry averages, implying market expectations of superior earnings growth. PLTR's P/E of 445.49 against an industry average of 31.10, and VRTX's 26.78 P/E versus its biomedical industry's -2.80, highlight these elevated growth expectations. This suggests that substantial future performance is already priced into these valuations.

While companies like SBA Communications (SBAC) and BWX Technologies (BWXT) have consistently beaten EPS expectations in the past year, several others have recent misses. Vertex Pharmaceuticals (VRTX) missed Q1 2025 consensus by -3.79%, and Diamondback Energy (FANG) missed Q3 2024 by -11.05%, indicating potential volatility. Hologic (HOLX) also shows a 143.06% increase in days to cover, signaling heightened short interest.

Key Decisions for Investors

• Closely monitor actual EPS results against elevated consensus forecasts for high-P/E growth stocks like Palantir and Franco-Nevada, as significant future performance is already priced in.
• For companies with recent EPS misses such as Vertex Pharmaceuticals and Diamondback Energy, scrutinize management commentary for forward guidance and any revisions to outlook.
• The substantial increase in Hologic's days to cover warrants careful consideration of short-term volatility and potential post-earnings price action.